The purpose of this observational study is to collect contemporary real-world treatment patterns, clinical outcomes, humanistic burden (including patient-reported disease-specific Health-related Quality of Life (HRQoL), and treatment- related adverse events (AEs) or adverse reactions (ARs) among Advanced Renal Cell Carcinoma (aRCC) patients initiating first-line systemic therapy.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Cohort 1
Primary diagnosis of aRCC (advanced Renal Cell Carcinoma) or metastatic RCC Medical history must be available from date of aRCC diagnosis Initiated 1LOT between April 2018 - March 2020
Cohort 2:
Primary diagnosis of aRCC (not amenable to curative surgery or radiation therapy/ AJCC Stage III unresectable) or metastatic RCC (AJCC Stage IV). Medical history must be available from date of aRCC diagnosis. Initiate 1LOT.
Exclusion Criteria:
Currently enrolled in a clinical trial for treatment of aRCC Any prior malignancy active within the previous 3 year, except for locally curable cancers that have been cured Any prior systemic therapy for aRCC, with the exception of neoadjuvant or adjuvant therapy (Cohort 2 only)
Other protocol-defined inclusion/exclusion criteria apply
